Three Metabolic Peptides, One Research Frame

The short version

Raw Wholesale Peptides is a reading digest, not a store. It collects what the published research literature actually says about three peptides that keep coming up in conversations about metabolic regulation and fat metabolism: AOD-9604, Tesamorelin, and MOTS-c. A peptide is a short chain of amino acids — the same building blocks as proteins, only far smaller. Each of these three was studied because it seems to act on some part of the body's metabolic machinery: shifting where fat is stored, encouraging the body's own hormone system to release growth hormone in a more physiological pattern, or activating the cellular energy-sensing switch (AMPK) that muscles use to handle glucose.

This digest does one job: it tells you, in plain language and with citations, what each peptide was tested on, in which species, and how far that evidence really reaches. Two of the three have almost no human data; one has a narrow FDA approval for a specific HIV-related condition. None is an approved medicine for general fat loss or metabolic optimization. We do not sell anything, we do not give medical advice, and we never list a human dose.

What are research peptides?

Proteins in the body — a hormone, an enzyme, a structural scaffold — are long chains of amino acids folded into a specific shape. A peptide is a much shorter chain of the same building blocks, sometimes only a handful of links long. Because they are small and specific, peptides can act like keys that fit particular molecular locks on cell surfaces or inside cells, switching certain processes on or off.

A research peptide is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, occasionally in early human pilots — but has not been approved by a regulator as a medicine for general use. Sellers describe these compounds as being for laboratory research only, and that framing matters: it means dosing, long-term safety, and real-world effectiveness in people are usually unestablished. When this site reports a number, it reports it the way the study did — for example, studied at 2 mg/day in HIV-infected adults in an RCT — never as a recommendation. Where a peptide is modified from a natural molecule, we say so, because that lineage is often the key to what it does.

How these three fit into metabolic research

The three peptides on this desk approach fat metabolism and metabolic regulation from different angles, which is exactly why they sit together.

• AOD-9604 is the lead. It is a synthetic sixteen-amino-acid analogue of the C-terminal lipolytic domain of human growth hormone, engineered to reproduce fat-metabolism activity while avoiding the growth-promoting, IGF-1-elevating effects of the intact hormone ^[6][4]. In rodent models it reduces body fat and up-regulates beta-3 adrenergic receptor expression in white adipose tissue. In pivotal human obesity trials — roughly 900 obese subjects across about six studies — it did not produce statistically significant weight loss versus placebo and the development programme was discontinued ^[3].
• Tesamorelin is the desk's one regulated compound. A 44-amino-acid GHRH analogue, it works by stimulating the pituitary's own growth-hormone-secreting cells to release GH in a physiological pulsatile rhythm; the resulting GH and IGF-1 promote lipolysis preferentially in visceral adipose tissue ^[12]. It holds an FDA approval for HIV-associated lipodystrophy — a specific condition causing excess abdominal fat in HIV patients on antiretroviral therapy — which is where its RCT evidence is strongest ^[9]. All other uses are off-label.
• MOTS-c is the newest and most mechanistically unusual. It is a 16-amino-acid peptide encoded not in the nuclear genome but inside the mitochondrial 12S rRNA gene — the only signaling peptide known to be mitochondrially encoded. Its best-characterized action is inhibiting the folate cycle to raise AICAR and activate AMPK, improving glucose handling primarily in skeletal muscle ^[15]. A 2024 study identified casein kinase 2 as a direct binding target ^[13]. There are no completed human efficacy trials.

Together they sketch metabolic intervention from several angles: a lipolytic fragment that failed human translation, a hormonal relay that succeeded in a narrow indication, and a mitochondrial signal that has not yet reached human trials. Use the directory to read each one, or compare these peptides side by side.

A note on how this digest reads the literature

Raw Wholesale Peptides is a cross-referenced literature digest. Each peptide page summarizes the peer-reviewed studies for that compound, cites them by number, and links to a single shared references list that aggregates every source across all three. Where the evidence is thin, single-lab, or preclinical, we say so plainly — that caution is part of the record, not an asterisk at the bottom. We describe research findings and the cited cautions that come with them; we do not recommend, prescribe, or sell. The aim is a precise, accurate map of what is known, so you can see where the science is solid and where it is still mostly mechanistic promise.